Although these 99mTc (half-life of 6 h, 90% γ, 140 keV) radiotracers exhibit lower sensitivity than PSMA-targeted PET radiotracer alternatives, particularly in the case of biochemical recurrence of prostate cancer at low PSA levels or low tumor volumes, they have potential utility in providing useful diagnostic information at high tumor volumes, assessing suitability for and response to PRRT and radioguided surgery for which detection of every site of small volume of disease is less critical (4,7,8). This evidence concerns the gene FOLH1 and prostate carcinoma.